Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Pramlintide (Symlin) peptide icon, one bubble per amino acidPramlintide (Symlin)37 residuesKCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTYEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Pramlintide (Symlin)

Beginner tier: 15 mcg, before each major meal (>=250 kcal or >=30 g carb) · FDA label

Weight LossFDA Approved
48 min half-life·Injection

Also known as: Symlin, AC137

A 37-amino-acid hormone that your pancreas stopped making. Pramlintide (Symlin) is the only FDA-approved synthetic analog of human amylin, co-secreted with insulin by beta cells after every meal. In type 1 diabetes, amylin production is essentially zero. In type 2 diabetes, it is severely impaired. Clinical trials confirmed lower post-meal glucose beyond what insulin alone achieves (PMID 14578242 (opens in a new tab)), with HbA1c drops of 0.2 to 0.6 percent and modest weight loss of 0.8 to 1.6 kg. AstraZeneca discontinued Symlin commercially in October 2025, making remaining specialty pharmacy stock the only access route. The black box warning for severe hypoglycemia in type 1 diabetes (16.8% incidence in the first three months) is not optional reading.

What Is Pramlintide (Symlin)?

Post-meal glucose spikes that insulin alone can't fix. That is the problem pramlintide was built to solve. Pramlintide acetate (brand name Symlin, CAS 151126-32-8) is a synthetic analog of human amylin, the 37-amino-acid peptide hormone that healthy beta cells co-secrete alongside insulin after each meal. Three proline substitutions at positions 25, 28, and 29 prevent the aggregation and amyloid formation that make native amylin unsuitable as a drug.

The FDA granted approval in March 2005, and pramlintide remained the only amylin analog on the market for two decades. It works through three mechanisms that insulin simply cannot replicate: slowing gastric emptying so glucose enters the bloodstream more gradually, suppressing inappropriate postprandial glucagon secretion from alpha cells, and promoting satiety through amylin receptors in the area postrema. The combination flattens post-meal glucose curves in a way that even optimized insulin regimens struggle to match.

Thompson and colleagues [1] gave pramlintide for 4 weeks to type 2 diabetes patients using insulin, and HbA1c fell 0.5 to 0.6 percent against 0.3 percent on placebo. In type 1 diabetes, Fineman's group [2] showed pramlintide blocked the meal-related rise in glucagon in two placebo-controlled studies. In the trials on the Symlin label, both populations lost 0.8 to 1.6 kg while placebo groups gained weight.

AstraZeneca pulled Symlin from the market in October 2025 (a commercial decision, not a safety-driven withdrawal or FDA recall). No generic exists. Remaining stock through specialty pharmacies is the only current access. Cagrilintide, the next-generation amylin analog from Novo Nordisk with weekly dosing and the CagriSema combination, is the pipeline replacement. The REDEFINE 1 trial (NEJM June 2025) posted 22.7% mean weight loss. Pramlintide did what it could with the technology of 2005; the field has moved on.

How Pramlintide (Symlin) Works

Three proline substitutions at positions 25, 28, and 29 separate pramlintide from native human amylin. Those substitutions prevent aggregation into amyloid fibrils, which is the structural problem that kept amylin itself from ever becoming a drug. Pramlintide binds to amylin receptors, heterodimers of the calcitonin receptor paired with receptor activity-modifying proteins RAMP1, RAMP2, or RAMP3, concentrated in the area postrema and hypothalamus.

Receptor activation triggers three distinct effects that work alongside insulin. First, vagal inhibition slows gastric emptying. Food takes longer to reach the small intestine, and glucose enters the bloodstream on a more gradual curve rather than in a postprandial spike. Second, glucagon secretion from pancreatic alpha cells is suppressed after meals. This reduces hepatic glucose output during the exact window when insulin is trying to clear circulating glucose. Third, central nervous system satiety signaling reduces food intake at the meal itself.

The glucagon suppression deserves extra attention. It is meal-specific. During hypoglycemia, the counter-regulatory glucagon response remains intact. Pramlintide does not blunt the body's ability to rescue itself from low blood sugar; it only blocks the inappropriate glucagon rise that follows eating. Three placebo-controlled studies by Amiel and colleagues found pramlintide left the hormone response to insulin-induced hypoglycemia unchanged in type 1 diabetes (PMID 16050943 (opens in a new tab)).

Subcutaneous injection reaches peak plasma concentration in approximately 20 minutes. The 48-minute half-life means each injection covers one meal. That is also why the drug requires three daily injections and why the field invested in cagrilintide: weekly dosing through a longer-acting amylin analog.

Pramlintide (Symlin) Benefits

  • Pramlintide benefits center on postprandial glucose control, satiety, and weight neutrality as an insulin adjunct.
  • Postprandial glucose control beyond insulin alone: in type 1 diabetes, mealtime pramlintide cut the 4-hour post-meal glucose excursion by 75% to over 100% versus insulin plus placebo (Weyer et al., PMID 14578242 (opens in a new tab)) and blocked the meal-related glucagon rise (Fineman et al.)[2].
  • HbA1c drops of 0.2 to 0.6 percent as add-on therapy, with T2D patients typically seeing the larger end of that range (Symlin FDA Prescribing Information, NDA 021332).
  • Weight loss of 0.8 to 1.6 kg in the label's trials, while placebo groups on insulin gained weight (Symlin FDA Prescribing Information). That reversal matters when every other diabetes drug in the regimen is pushing the scale upward.
  • Satiety signaling reduces caloric intake at each meal. Community users on r/diabetes_t1 frequently describe feeling full with smaller portions, a subjective effect that aligns with the central amylin receptor mechanism.
  • Over 20 years of post-marketing safety data following the 2005 approval. The long-term safety profile is well characterized, which is unusual for the peptide space.
  • Some T1D users report insulin dose reductions of up to 30% once pramlintide is optimized, turning it into both a glucose-flattening and insulin-sparing adjunct.

Pramlintide (Symlin): Science vs Community Consensus

Partially Aligned
Scientific Evidence
Strong
Based on 8 key studies·FDA-approved

FDA-approved amylin analog with strong evidence for postprandial glucose reduction in T1D and T2D as insulin adjunct.

Dosing studied: T1D: 15–60 mcg SC before each major meal (3× daily). T2D: 60–120 mcg SC before each major meal (3× daily). T1D and T2D dose ceilings are DIFFERENT: T1D max is 60 mcg per meal.
Read the evidence (key study, limitations)

HbA1c reduction 0.2–0.6%; lower post-meal glucose beyond insulin alone. Modest weight loss 0.8–1.6 kg. Multiple phase 3 RCTs support efficacy. Black box warning for severe hypoglycemia in T1D (16.8% incidence in first 0–3 months). No new major clinical trials since 2014 label update: research momentum has shifted to next-gen amylin analogs (cagrilintide, petrelintide).

Key Study

Symlin FDA Prescribing Information (2014, NDA 021332); Thompson et al. Diabetes Care 1998 (PMID 9614619); Fineman et al. Metabolism 2002 (PMID 11979398)

Limitations

T1D max dose (60 mcg) vs T2D max dose (120 mcg) creates a meaningful safety distinction that can be lost in simplified dosing presentations. No head-to-head trials vs GLP-1 agonists. Drug commercially discontinued Oct 2025: access severely limited. Protein binding (~60%) and key drug interactions (acetaminophen, norgestrel, ampicillin) absent from most summaries.

Community Experience
Moderate
3.0/5
Based on ~20–50 Reddit threads (r/diabetes_t1, r/diabetes)

Community confirms glycemic benefit but adherence is poor.

Community dosing: Most T1D users report settling at 30–45 mcg per meal; few reach the 60 mcg target due to persistent nausea. T2D users more commonly reach the 120 mcg target.
Read the reports (what users report 5, common issues 6)

Nausea burden and 3× daily injection frequency on top of existing insulin regimen are the primary barriers. Most reports come from r/diabetes_t1 and diabetes.co.uk. Overall sentiment ~3.0/5.

What users report (5)
  • Post-meal glucose flattening beyond what insulin alone achieves
  • Earlier satiety and smaller portion sizes
  • Insulin dose reductions of up to 30% reported by some T1D users
  • Weight-neutral vs insulin monotherapy; modest weight loss in adherent users
  • Useful adjunct for users with high postprandial excursions despite optimized insulin
Common issues (6)
  • Significant nausea in 30–50% of users, especially weeks 1–2: leading cause of discontinuation
  • Three injections daily on top of insulin burden cited as unsustainable by most
  • Severe hypoglycemia within 3 hours of injection if mealtime insulin not reduced 50%
  • T1D vs T2D dose confusion: 120 mcg is T2D only; T1D ceiling is 60 mcg
  • Drug commercially discontinued Oct 2025; access from remaining specialty pharmacy stock only
  • Subset of users report no measurable glycemic or weight benefit
Partially Aligned

Science and community agree on the glycemic mechanism and postprandial benefit. They diverge on practicality: clinical trials show statistically significant HbA1c and weight improvements, but real-world adherence is low due to nausea and injection frequency. Notably, community dosing closely mirrors the FDA label (T1D titration, 50% insulin reduction), which is atypical; this is one of the few peptides where off-label community use essentially tracks the approved protocol.

Pramlintide (Symlin) Dosage Guide

FDA LabelSymlin (pramlintide acetate) FDA Prescribing Information (2014)Source (opens in a new tab)
LevelDose / InjectionFrequency
Beginner15 mcgBefore each major meal (>=250 kcal or >=30 g carb)
Moderate60 mcgBefore each major meal (>=250 kcal or >=30 g carb)
Aggressive120 mcgBefore each major meal (>=250 kcal or >=30 g carb)
Note:

Symlin ships as a pre-filled solution at 1000 mcg/mL. No lyophilized powder, no reconstitution, no bacteriostatic water. The math for syringe units is straightforward on a U-100 insulin syringe: 15 mcg equals 1.5 units, 30 mcg equals 3 units, 60 mcg equals 6 units, 120 mcg equals 12 units. If you're drawing from a vial rather than a pen (remaining stock varies), confirm the concentration is 1000 mcg/mL before calculating. A wrong concentration assumption creates a proportional dosing error.

The thing most people miss: T1D and T2D dose ceilings are different. Type 1 diabetes max is 60 mcg per meal. Type 2 diabetes max is 120 mcg per meal. A T1D patient taking 120 mcg is taking double their approved maximum. Always confirm diabetes type before dosing above 60 mcg.

Inject within 15 minutes before a major meal containing at least 250 kcal and 30g of carbohydrates. Skipping a meal after injecting is how hypoglycemia happens when there is no incoming glucose to offset the drug's effects. If you forget a dose, skip it entirely and resume at the next major meal. Never double up.

Cycling

No scheduled off period.

Continuous therapy: pramlintide is designed for ongoing daily use alongside insulin. There is no cycling protocol. Stopping pramlintide requires re-adjusting insulin doses upward to compensate for the loss of glucagon suppression and gastric emptying effects.

Calculate your Pramlintide (Symlin) dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Pramlintide (Symlin) Protocols by Goal

beginnerFDA LabelOngoing (continuous)
Initiation
Wk 1–2
15 mcg · Before each major meal (3× daily) · Subcutaneous
Titration
Wk 3–8
30–60 mcg · Before each major meal (3× daily) · Subcutaneous
Maintenance
Wk Ongoing
30–60 mcg · Before each major meal (3× daily) · Subcutaneous

Expected: Lower post-meal glucose beyond insulin alone; HbA1c reduction 0.2–0.4%; weight loss 0.8–1.6 kg

Monitor: Monitor blood glucose before each meal and 1, 2, 3 hours post-meal during the first 4 weeks. Highest hypoglycemia risk is within 3 hours of injection.

How to Inject Pramlintide (Symlin)

  1. 1
    Confirm your diabetes type

    T1D starts at 15 mcg per meal; T2D starts at 60 mcg per meal. This distinction is a safety boundary, not a suggestion.

  2. 2
    Step 2

    Reduce your mealtime rapid-acting insulin dose by 50% on the day you start pramlintide. This is an FDA mandate, not optional. The insulin reduction compensates for the glucose-lowering effects pramlintide adds.

  3. 3
    Draw up the correct dose using a U-100 insulin syringe

    For a 1000 mcg/mL vial: 15 mcg equals 1.5 units, 30 mcg equals 3 units, 60 mcg equals 6 units, 120 mcg equals 12 units.

  4. 4
    Step 4

    Inject subcutaneously into the abdomen or thigh within 15 minutes before a major meal. Choose an injection site at least 2 inches away from wherever you plan to inject insulin. Never mix pramlintide and insulin in the same syringe; they are chemically incompatible.

  5. 5
    Step 5

    Inject your mealtime insulin separately in the second site.

  6. 6
    Step 6

    T1D titration: increase by 15 mcg every 3 to 7 days as tolerated. Target 30 to 60 mcg per meal. If nausea prevents reaching 45 to 60 mcg, 30 mcg is an acceptable maintenance dose. Never exceed 60 mcg.

  7. 7
    Step 7

    T2D titration: increase from 60 mcg to 120 mcg after 3 to 7 days if tolerated. If nausea prevents reaching 120 mcg, remain at 60 mcg.

  8. 8
    Step 8

    Monitor blood glucose before each meal and at 1, 2, and 3 hours post-injection during the first 4 weeks. The hypoglycemia window extends to 3 hours after each dose.

  9. 9
    Step 9

    Storage: refrigerate unopened pens or vials at 2 to 8 degrees Celsius. Once in use, store at room temperature (up to 25 degrees Celsius) or refrigerated for up to 30 days. Never freeze.

  10. 10
    Use a 29 to 31 gauge needle, 8mm or shorter

    Standard insulin syringe needles work.

Pramlintide (Symlin) Stacking Protocols

Works With

Rapid-acting insulin (lispro, aspart, glulisine)

Required co-administration per FDA label. Pramlintide is never used standalone: it complements but does not replace mealtime insulin. Must reduce insulin dose 50% at initiation.

Administer pramlintide, then insulin in a separate syringe at least 2 inches away. Never mix in same syringe (chemically incompatible).

Metformin

Common T2D background oral therapy. No documented pharmacokinetic interaction with pramlintide. Frequently co-prescribed as part of standard T2D regimen.

Cagrilintide

Next-generation amylin analog (once weekly dosing). Not stacked with pramlintide: intended as replacement. CagriSema Phase 3 (REDEFINE 1, NEJM June 2025) achieved 22.7% mean weight loss; Novo Nordisk filed for FDA approval in 2025. Pramlintide is being clinically superseded.

Semaglutide

Mechanistically complementary (GLP-1 + amylin pathways). NOT recommended without close monitoring: overlapping GI effects and additive hypoglycemia risk. The evidence-based combination is cagrilintide + semaglutide (CagriSema), not pramlintide + semaglutide.

Avoid

Alpha-glucosidase inhibitors (acarbose, miglitol)

Both delay carbohydrate absorption: additive effect may cause excessive glucose lowering and severe GI symptoms. FDA label: concurrent use not recommended.

Do not combine
Anticholinergic agents

Additive gastric emptying delay. Combined use risks unpredictable and prolonged glucose absorption variability.

Do not combine
Acetaminophen (paracetamol)

Pramlintide delays gastric emptying, reducing acetaminophen Cmax by 20–29%. Take acetaminophen ≥1 hour before or ≥2 hours after pramlintide injection if rapid absorption is needed. FDA label interaction.

Oral contraceptives (norgestrel-containing)

Norgestrel Cmax reduced ~30% when co-administered due to delayed gastric emptying. Take OCP at least 1 hour before pramlintide. FDA label interaction.

Estimated Cost

Brand Price
SymlinPen 60: ~$995–$1,100/month; SymlinPen 120: ~$1,200–$1,305/month (typical US cash price, where remaining stock exists). Official supply discontinued Oct 2025. Covered under insurance Tier 3–4 for insulin-using T1D and T2D patients; prior authorization typically required. Patient assistance programs likely winding down.

Pricing updated 2026-04-09

Pramlintide (Symlin) Side Effects

The black box warning comes first. Pramlintide used with insulin carries a risk of severe hypoglycemia, particularly in type 1 diabetes. The FDA label reports 16.8% incidence of severe hypoglycemia in T1D patients during the first zero to three months of treatment. Severe episodes can occur within three hours of injection. This is not a theoretical risk buried in post-marketing data; it is the reason the prescribing information mandates a 50% mealtime insulin dose reduction at initiation and frequent blood glucose monitoring during the first four weeks.

Nausea is the most common side effect and the primary reason patients discontinue. Published trial rates range from 10 to 59% depending on the population and trial design. Community data from r/diabetes_t1 and diabetes.co.uk aligns with the higher end of that range, with 30 to 50% of users describing nausea in the first one to two weeks as "significant enough to consider stopping." It typically peaks during the titration phase and fades by week four to eight for patients who persist.

Vomiting affects 6 to 14% of patients across trials. Reduced appetite (2 to 9%) is expected and somewhat intentional; the satiety mechanism works on the area postrema. Headache, abdominal pain, and fatigue occur at low but measurable rates.

Injection site reactions (redness, swelling, bruising) show up occasionally. Three daily subcutaneous injections on top of an existing insulin regimen create a lot of injection sites over time. Rotating between the abdomen and thigh helps.

Gastroparesis is an absolute contraindication. Pramlintide slows gastric emptying by design. In someone whose stomach already empties too slowly, this creates dangerous glucose unpredictability and severe GI symptoms.

The drug interaction profile matters more than most summaries acknowledge. Pramlintide delays gastric emptying enough to reduce acetaminophen peak concentration by 20 to 29%. Norgestrel (oral contraceptive) peak concentration drops roughly 30%. Ampicillin absorption is delayed by about 60 minutes. Any oral medication requiring rapid or predictable absorption needs a timing buffer: take it one hour before or two hours after pramlintide.

Pregnancy and breastfeeding: no adequate safety data exists. Amylin receptor effects on fetal development have not been studied. Pediatric patients under 18 are excluded from the approved indication.

When to stop and seek medical help: recurrent severe hypoglycemia despite proper insulin reduction, development of gastroparesis symptoms, persistent severe nausea at the lowest dose after adequate titration, or signs of allergic reaction.

Common Issues & Solutions

Nausea on initiation: Start at the lowest dose (15 mcg T1D, 60 mcg T2D), ensure the meal contains ≥250 kcal and ≥30g carbs, and titrate slowly (no faster than every 3 days). Nausea peaks at weeks 1–2 and typically resolves by week 4–8 for users who stay the course.

Hypoglycemia within 3 hours of injection: Almost always caused by failing to reduce mealtime insulin by 50% at initiation, or eating a smaller meal than expected. Verify the 50% insulin reduction is applied and that the meal meets the ≥30g carb threshold. Monitor glucose at 1 and 3 hours post-injection during the first 4 weeks.

Missed dose before a meal: Skip the dose entirely: do not take pramlintide retroactively without food and do not double-dose at the next meal. Resume at the next major meal.

T1D vs T2D dose confusion (P0 safety): T1D max is 60 mcg per meal. T2D max is 120 mcg per meal. A T1D patient taking 120 mcg is taking double the approved maximum. Always confirm diabetes type before setting any dose above 60 mcg per meal.

Concurrent oral medications: Take time-sensitive oral drugs (antibiotics, OCPs, narrow-TI medications) at least 1 hour BEFORE pramlintide injection, or 2 hours AFTER. Pramlintide reliably delays gastric emptying for drugs taken within this window.

Ask AI about this page

Ask AI for a second opinion on Pramlintide (Symlin) dosing and side effects

Contraindications

  • Confirmed gastroparesis or significant gastrointestinal motility disorder: pramlintide further delays gastric emptying
  • Hypoglycemia unawareness: the combined hypoglycemia risk with insulin is too high
  • Known hypersensitivity to pramlintide, metacresol, or any excipient in Symlin
  • HbA1c > 9% or recurrent severe hypoglycemia in the past 6 months: glucose instability makes dose titration unsafe
  • Poor compliance with insulin regimen, glucose monitoring, or physician follow-up
  • Pregnancy or breastfeeding: no adequate safety data; amylin receptor effects on fetal development not studied
  • Pediatric patients under 18: not approved for use in children
  • Concurrent use of medications that slow GI motility (e.g., anticholinergics, alpha-glucosidase inhibitors)

Drug Interactions

  • Mealtime insulin (rapid-acting): MUST reduce dose by 50% when starting pramlintide; severe hypoglycemia risk
  • Sulfonylureas and meglitinides: additive hypoglycemia risk; dose adjustment may be needed
  • Alpha-glucosidase inhibitors (acarbose, miglitol): both delay carbohydrate absorption; combined use not recommended
  • Anticholinergic agents: additive gastric emptying delay; avoid concurrent use
  • Oral medications requiring rapid GI absorption: pramlintide slows gastric emptying and may delay absorption of concurrently administered oral drugs; take oral medications 1 hour before or 2 hours after pramlintide
  • GLP-1 receptor agonists (semaglutide, liraglutide): overlapping GI slowing effects; combined use not studied and may increase nausea and hypoglycemia risk

Product Quality

Recommended Monitoring

TestWhenTarget
Blood glucose (CGM or fingerstick)Before each meal and 1, 2, 3 hours post-meal during first 4 weeks of each dose levelPostprandial <10 mmol/L (180 mg/dL); pre-meal 4–7 mmol/L (72–126 mg/dL)
HbA1cBaseline, then every 3 months<7% for most T1D/T2D patients; individualize per clinical judgment
2-hour postprandial glucose deltaMonthly spot-checks after reaching maintenance doseNot listed
Body weightMonthlyNot listed
Blood glucose (CGM or fingerstick)

Detect hypoglycemia within 3 hours of injection: the primary black box warning risk. Critical during titration.

HbA1c

Primary efficacy endpoint. Expect 0.2–0.6% reduction from baseline after 3+ months at maintenance dose.

2-hour postprandial glucose delta

Primary mechanism of action is postprandial glucose reduction: if the delta is not improving versus the pre-pramlintide baseline, reassess dose and timing.

Body weight

Secondary outcome: modest weight loss expected (0.8–1.6 kg). Weight gain on pramlintide suggests insulin dose re-optimization is needed.

Pramlintide (Symlin) Before and After

Days 1-7

Starting at the lowest dose (15 mcg for T1D, 60 mcg for T2D). Nausea is most common during this period. Mealtime insulin has been cut by 50%. Blood glucose may run slightly higher as the insulin-pramlintide balance is established. Frequent monitoring required.

Weeks 1-4

Titrating upward every 3-7 days as tolerated. Post-meal glucose spikes begin to flatten noticeably. Nausea typically peaks and then starts to fade. This is the highest-risk window for hypoglycemia: watch for symptoms within 3 hours after injection. Insulin doses are being fine-tuned.

Weeks 5-12

Reaching maintenance dose (30-60 mcg for T1D, 120 mcg for T2D). Post-meal glucose control becomes consistent. GI side effects have largely resolved. Mild weight loss of 0.5-1 kg may be noticeable. HbA1c starts to trend downward.

Months 3-6

Full glycemic benefit realized. HbA1c reduced by 0.2-0.6% from baseline. Weight stable or slightly decreased compared to insulin-only regimen. Postprandial glucose control is predictable. Insulin doses have been re-optimized.

Months 6-12+

Long-term maintenance. Glycemic improvements sustained. Weight remains stable or slightly below pre-pramlintide levels. Continued adherence to pre-meal timing is necessary for effectiveness.

What to Expect

Days 1 through 7, Initiation and Insulin Adjustment: You start at the lowest dose (15 mcg for T1D, 60 mcg for T2D) and cut your mealtime insulin by half. Glucose may run slightly higher than usual while the new balance gets established. Nausea is the dominant experience this week and the number one reason people quit early. No significant postprandial benefit yet; this period is about tolerance, not results.

Weeks 1 through 4, Titration and Hypoglycemia Watch: Dose increases happen every 3 to 7 days as tolerated. Post-meal glucose spikes begin flattening noticeably. This is the highest-risk window for severe hypoglycemia, with the FDA label reporting 16.8% incidence in T1D patients during the first zero to three months. Nausea typically peaks then starts fading. Users who push through week 1 describe the first real postprandial flatness as genuinely encouraging. Watch for hypoglycemia symptoms within 3 hours of every injection.

Weeks 5 through 12, Maintenance Dose and GI Adaptation: You've reached 30 to 60 mcg (T1D) or 120 mcg (T2D). GI side effects have largely resolved. Post-meal glucose control is consistent. Mild weight loss of 0.5 to 1 kg may be visible. Adherent users describe smaller meals feeling adequate, which tracks with the satiety mechanism. The injection routine is habitual by now, though the 3x daily frequency remains the biggest long-term complaint.

Months 3 through 6, HbA1c Improvement: Lab work reflects the benefit. HbA1c is down 0.2 to 0.6 percent from baseline. Weight is stable or slightly below where it was on insulin alone. Some T1D users report insulin dose reductions of up to 30%. The postprandial glucose pattern is predictable. Insulin doses have been re-optimized from the initial 50% reduction.

Months 6 through 12 and beyond, Long-Term Maintenance: Glycemic improvements hold with continued use. No evidence of tolerance or loss of efficacy over time. Long-term adherent users are self-selected; most who found the injection burden unsustainable have already stopped. Drug availability is now a practical concern following the October 2025 commercial discontinuation.

Detailed Timeline: Science vs Community

Days 1–7
Science

Starting dose (15 mcg T1D, 60 mcg T2D). Mealtime insulin cut by 50%: glucose may run slightly higher while the new balance is established. No significant postprandial benefit expected yet.

Community

Nausea is the dominant experience in week 1 and the primary dropout driver. Users describe the 50% insulin reduction as counterintuitive. Glucose runs unpredictably during this adjustment phase.

Weeks 1–4
Science

Titrating upward every 3–7 days. Post-meal glucose spikes begin flattening. Highest hypoglycemia risk window (T1D: 16.8% severe hypoglycemia incidence per FDA label in first 0–3 months).

Community

Users who push through week 1 begin noticing postprandial flatness. Nausea fades for most by week 3–4. Hypoglycemia episodes reported, typically from insufficient insulin reduction or smaller-than-planned meals.

Weeks 5–12
Science

Maintenance dose established. GI effects largely resolved. Post-meal glucose control consistent. Weight may decrease 0.5–1 kg.

Community

Adherent users describe meaningful glycemic improvement. Satiety is frequently noted: smaller meals feel adequate. Injection routine is habitual but 3× daily frequency remains the most-cited long-term complaint.

Months 3–6
Science

HbA1c reduced 0.2–0.6% from baseline. Weight stable or slightly reduced vs insulin-only. Postprandial glucose control predictable.

Community

Lab improvements visible at 3-month A1c check. Some report insulin dose reductions of up to 30%. Weight-neutral outcome reported even without explicit weight loss: no insulin-related weight gain.

Months 6–12+
Science

Sustained HbA1c and postprandial glucose improvements with continued use. No evidence of tolerance or loss of efficacy over time.

Community

Long-term adherent users are self-selected. Primary ongoing complaint is injection burden. Drug availability now an emerging practical concern following Oct 2025 commercial discontinuation.

Pharmacokinetics

Half-Life
48min
Bioavailability
SC: ~30-40%
Tmax
~20 minutes (SC)
Data Confidence
high

Source: FDA prescribing information: approximately 48 minutes in healthy subjects (SC administration)

Pharmacokinetics: Active Dose Over Time

t½ = ~48 minutes

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Molecular Profile

Amino Acids
37
Sequence
KCNTATCATQRLANFLVHSSNNFGPILPPTNVGSNTY
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 151126-32-8

Who Should Consider Pramlintide (Symlin)

  • Adults with type 1 diabetes who have not achieved glycemic targets despite optimized insulin therapy
  • Adults with type 2 diabetes using mealtime insulin who need better postprandial glucose control
  • Insulin-using diabetics experiencing weight gain who want a weight-neutral or weight-reducing adjunct
  • Patients with high postprandial glucose excursions despite pre-meal insulin dosing
  • Adults willing to add pre-meal injections for tighter glucose control

Related Peptides

What Changed for Pramlintide (Symlin)

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations

References

  1. [1]Pramlintide improves metabolic profile in type 2 diabetes using insulin (Diabetes Care 1998) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Pramlintide corrects postprandial hyperglucagonemia in type 1 diabetes (Metabolism 2002) (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Pramlintide selectively delays gastric emptying (Am J Physiol 2000) (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]FDA NDA 021332

Related Tools

Storage & Stability

Before Reconstitution
Not applicable: supplied as pre-filled solution
After Reconstitution
Refrigerate unopened pens at 2-8°C. Once in use, store at room temperature or refrigerated for up to 30 days. Do not freeze.
Temperature
2-8°C (36-46°F) until opened; up to 25°C (77°F) once in use

Frequently Asked Questions

Because pramlintide slows gastric emptying and suppresses glucagon, meaning glucose enters your blood more slowly after meals. If you take the same insulin dose, it'll peak while your food is still in your stomach: causing severe hypoglycemia within 1-3 hours. The FDA mandates a 50% mealtime insulin reduction at initiation. You fine-tune doses upward from there.

No. For T1D the approved target is 30-60 mcg before each major meal. The 120 mcg dose is only for T2D. If you can't tolerate 45-60 mcg due to nausea, 30 mcg is an acceptable maintenance dose.

Different mechanism. Pramlintide works mainly by slowing gastric emptying and promoting satiety through area postrema receptors, not gut hormone signaling like GLP-1s. Weight loss is more modest (0.8-1.6 kg in trials vs 5-15% with semaglutide). But it uniquely combines with insulin therapy without needing a separate GLP-1 injection.

Never. The FDA label explicitly states they must be separate injections and should never be mixed: they're chemically incompatible when combined. Use separate syringes and inject at sites at least 2 inches apart.

Skip it and wait for your next major meal. Don't double-dose to make up for it. Taking pramlintide without eating risks hypoglycemia since there's no incoming glucose to offset its effects.